Category Archives: IP

After Delays, Project DataSphere Rolls Out

An industry and academic data-sharing project went live on Tuesday, nearly a year after the platform was expected to launch. Visitors to the site – no credentials needed – can register and access de-identified clinical data from the comparator arms of nine oncology trials, with more to come. Project DataSphere, the newest data transparency and […]
Also posted in Biotech, Corporate Responsibility, Europe, FDA, Global, leadership, Legal, R&D, Strategy, Technology | Tagged , , , , , , , , , | Leave a comment

Obama Budget Takes Slap at Pharma

Despite a slight boost in funding for the Food and Drug Administration and stronger tax incentives for investment in R&D, significant changes in Medicare drug reimbursement and coverage policies have biopharmaceutical companies up in arms.
Also posted in Biotech, Legal, R&D, Regulatory | Tagged , , , | Leave a comment

Weak IP Protection Threatens Asia-Pac Biotech Boom

The Asia-Pacific (APAC) region is experiencing a significant boom in the volume of private equity and venture capital  investments in biotechnology. According to research and consulting firm GlobalData, healthcare private equity investment in APAC increased by 125.8% between 2011 and 2013,  whereas deal activities in Europe and North America decreased by 30.5% and 2.5% between 2012 […]
Also posted in Deals, Emerging Markets, Global | Tagged , , , | Leave a comment

Innovation on the Rise in India

India has a name when it comes to generic drug development. According to a recent research on patent applications carried out by Withers & Rogers, innovation by Indian pharmaceutical companies has increased over the past few years; however, the quality did not match the standard seen in Europe. The research was conducted using a software […]
Also posted in Global, R&D | Tagged , , | Leave a comment

Momenta CEO Rebuffs Teva's Copaxone Defense

Momenta Pharmaceuticals’ CEO Craig Wheeler said comments made by Teva leadership about a “purported” generic of Copaxone are “kind of humorous.” Teva’s Copaxone, a multiple sclerosis drug that earns nearly $4 billion a year, is approaching patent expiry – and possible generic competition – on May 24. Assuming FDA approves a generic version of Copaxone, […]
Also posted in Biotech, FDA, leadership, Legal, People, pricing, R&D, Regulatory, Strategy | Tagged , , , , , , , | Leave a comment
  • Categories

  • Meta